-
Mashup Score: 0
By 2040, the number of blindness and vision loss cases are estimated to increase by roughly 50% across Brazil, Russia, India, China, and South America, a new study found.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3From the VISION Trial: Improved Patient Outcomes with Lutetium-PSMA-617 - Karim Fizazi - 6 month(s) ago
In a discussion between Alicia Morgans and Karim Fizazi, they explore the quality of life outcomes from the VISION trial, published in Lancet Oncology. This Phase III trial examines the effects of Lutetium-PSMA-617 (also known as Pluvicto) on heavily pretreated metastatic castration-resistant prostate cancer patients. The study demonstrates a significant 38% reduction in the risk of death….
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
From the #VISION trial: Improved patient outcomes with lutetium-PSMA-617. Karim Fizazi, MD, PhD @GustaveRoussy joins @CaPsurvivorship @DanaFarber in this discussion on the quality of life outcomes from the VISION trial, published in @TheLancetOncol > https://t.co/oyV97QM19P https://t.co/cadr2QUlty
-
-
Mashup Score: 0Assessing Reader Variability in PSMA-PET/CT Scan Interpretation: A Substudy of the VISION Trial, Journal Club - Rashid Sayyid & Zachary Klaassen - 6 month(s) ago
Rashid Sayyid and Zach Klaassen analyze an ad hoc analysis from the VISION study, published in the Journal of Nuclear Medicine. The study investigates the agreement between readers in the interpretation of 68Ga-PSMA-11 PET/CT scans to determine patient eligibility for 177Lu-PSMA-617 Radioligand Therapy in the treatment of prostate cancer. They elaborate on the study’s methodology, including the…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Assessing reader variability in PSMA-PET/CT scan interpretation: a substudy of the #VISION trial. A #JournalClub discussion with @RKSayyid @UofT & @zklaassen_md @GACancerCenter on UroToday > https://t.co/AZFPcAgcNz https://t.co/TmhOwlc9am
-
-
Mashup Score: 2Improving mCRPC Outcomes: VISION Study Highlights Lu-PSMA-617 Impact on Survival and Quality of Life, Journal Club - Rashid Sayyid & Zachary Klaassen - 7 month(s) ago
Rashid Sayyid and Zach Klaassen, dissect a publication from the VISION study regarding health-related quality of life and pain outcomes with Lu-PSMA-617+ Standard of Care versus Standard of Care alone in patients with mCRPC. This study, conducted across 84 global centers, reveals that the addition of Lu-PSMA-617 to standard care significantly improved overall survival rates from 11.3 to 15.3…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Improving #mCRPC outcomes: #VISION Study highlights Lu-PSMA-617's impact on survival and QoL. @RKSayyid @UofT & @zklaassen_md @GACancerCenter join in this #JournalClub discussion on UroToday > https://t.co/l4Hs32h5c1 @TheLancetOncol https://t.co/S1bsIsvuX0
-
-
Mashup Score: 0From the VISION Trial: Improved Patient Outcomes with Lutetium-PSMA-617 - Karim Fizazi - 7 month(s) ago
In a discussion between Alicia Morgans and Karim Fizazi, they explore the quality of life outcomes from the VISION trial, published in Lancet Oncology. This Phase III trial examines the effects of Lutetium-PSMA-617 (also known as Pluvicto) on heavily pretreated metastatic castration-resistant prostate cancer patients. The study demonstrates a significant 38% reduction in the risk of death….
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
From the #VISION trial: Improved patient outcomes with lutetium-PSMA-617. Karim Fizazi, MD, PhD @GustaveRoussy joins @CaPsurvivorship @DanaFarber in this discussion on the quality of life outcomes from the VISION trial, published in @TheLancetOncol > https://t.co/oyV97QM19P https://t.co/UFdx1EXG0m
-
-
Mashup Score: 0LASIK Enhancements: Handle with Care - 7 month(s) ago
D espite LASIK’s accuracy, enhancements simply come with the territory. E very once in a while a target is missed or a patient from years ago will show up with visual complaints and refractive surgeons must consider time, technique and potential risks of retreatment. We asked some veteran refractive surgeons for their insight and pearls for these rare but unavoidable situations. Enhancements typically fall into two categories: early and late. Early enhancements take place within the first few months of
Source: www.reviewofophthalmology.comCategories: Latest Headlines, OphthalmologyTweet-
LASIK Enhancements: Handle with Care Refractive surgeons say the keys to managing these cases are patience and precision. https://t.co/c6k5HV4Hfw #ophthalmology #eyecare #eyesurgeon #eyesurgery #LASIK #refractivesurgery #ophthalmologist #vision https://t.co/08OpJQfK7o
-
-
Mashup Score: 6Assessing Reader Variability in PSMA-PET/CT Scan Interpretation: A Substudy of the VISION Trial, Journal Club - Rashid Sayyid & Zachary Klaassen - 7 month(s) ago
Rashid Sayyid and Zach Klaassen analyze an ad hoc analysis from the VISION study, published in the Journal of Nuclear Medicine. The study investigates the agreement between readers in the interpretation of 68Ga-PSMA-11 PET/CT scans to determine patient eligibility for 177Lu-PSMA-617 Radioligand Therapy in the treatment of prostate cancer. They elaborate on the study’s methodology, including the…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Assessing reader variability in PSMA-PET/CT scan interpretation: a substudy of the #VISION trial. A #JournalClub discussion with @RKSayyid @UofT & @zklaassen_md @GACancerCenter on UroToday > https://t.co/AZFPcAgcNz https://t.co/4b7jCizkCO
-
-
Mashup Score: 0From the VISION Trial: Improved Patient Outcomes with Lutetium-PSMA-617 - Karim Fizazi - 8 month(s) ago
In a discussion between Alicia Morgans and Karim Fizazi, they explore the quality of life outcomes from the VISION trial, published in Lancet Oncology. This Phase III trial examines the effects of Lutetium-PSMA-617 (also known as Pluvicto) on heavily pretreated metastatic castration-resistant prostate cancer patients. The study demonstrates a significant 38% reduction in the risk of death….
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
From the #VISION trial: Improved patient outcomes with lutetium-PSMA-617. Karim Fizazi, MD, PhD @GustaveRoussy joins @CaPsurvivorship @DanaFarber in this discussion on the quality of life outcomes from the VISION trial, published in @TheLancetOncol > https://t.co/oyV97QM19P https://t.co/5U0crvs6KA
-
-
Mashup Score: 0Highlights from the TFOS Lifestyle Reports - 8 month(s) ago
An interview with Christopher Starr, MD By Christine Yue Leonard, Senior Associate Editor D ry eye has a profound effect on quality of life. While we have a full armamentarium of treatments to offer patients, we can’ t always account for the impact of certain day-to-day lifestyle choices or situations when managing this chronic and often debilitating disease. Patients often want to know what else they can do to get through each day, in addition to the dry-eye treatments provided by their eye-care provider.
Source: www.reviewofophthalmology.comCategories: Latest Headlines, OphthalmologyTweet-
Highlights from the TFOS Lifestyle Reports A selection of key takeaways from the largest global dry-eye panel to date. https://t.co/bAFYJa8GLV #ophthalmology #eyecare #dryeye #cornea #dryeyedisease #TFOSLifestyle #TFOS #ophthalmologist #vision https://t.co/04cwpMsDFn
-
-
Mashup Score: 2Association Between Health Insurance and Vision Testing - 8 month(s) ago
This survey study assesses rates of vision testing by pediatrician or other primary care practitioners among insured and uninsured persons aged 3 to 17 years.
Source: jamanetwork.comCategories: General Medicine News, Latest HeadlinesTweet-
Few #children—especially those with safety-net insurance—get #vision checked at checkups @umich https://t.co/Qkokotca6O https://t.co/S9tzTLcn5D
-
Blindness and #vision loss burdens is projected to increase in Brazil, Russia, India, China, and South Africa by 2040, according to a new study led by Jianqi Chen, MD, @SunYatsen_Uni. https://t.co/2woNmH2jjN https://t.co/WxJyM4Vc3X